Tenet Healthcare Posts Lower Sales, Profits On Unfavorable Impact Of Cyber Attack

• Tenet Healthcare Corp's (NYSE: THC) Q2 FY22 adjusted EPS came in at $1.50, down from $1.59 a year ago and beating the management guidance of $1.18-$1.45 and the consensus of $1.05.

• Net operating revenue reached $4.64 billion, down 6.4% Y/Y, missing the consensus of $4.82 billion and the management guidance of $4.8 billion - $5.0 billion.

• Hospital segment sales declined 11% to $3.65 billion primarily due to the sale of Miami-area hospitals and the unfavorable impact of the cybersecurity incident.

• The cybersecurity incident contributed to same-hospital adjusted admissions for Q2 decreasing 5.3% Y/Y.

• The company estimates the cyber attack had an unfavorable impact of approximately $100 million on adjusted EBITDA during Q2. Adjusted EBITDA was $843 million versus $834 million a year ago.

• Net income reached $38 million, down from $119 million last year.

• Outlook: Tenet forecasts Q3 FY22 sales of $4.7 billion - $4.9 billion, compared to the consensus of $4.92 billion.

• It expects an adjusted EPS of $1.14 - $1.36, compared to the consensus of $1.29.

• For FY22, the company expects sales of $19 billion - $19.4 billion, below the prior guidance of $19.5 billion - $19.9 billion and the consensus of $19.74 billion.

• It sees an adjusted EPS of $5.80 - $7.00, compared to the earlier guidance of $5.86 - $7.03 and the consensus of $6.22.

• Price Action: THC shares closed 4.76% higher at $62.50 during after-hours trading on Thursday.

See more from Benzinga

• With All Eyes On Lecanemab Read Out In Alzheimer's, Uncertainty Overshadows Biogen's Q2 Beat

• This Penny Stock Touts Encouraging Long-Term Data For Hemophilia Gene Therapy

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.